NCT06657053

Brief Summary

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied. The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
145

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 22, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 24, 2024

Completed
9 days until next milestone

Study Start

First participant enrolled

November 2, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

October 24, 2024

Status Verified

October 1, 2024

Enrollment Period

4 months

First QC Date

October 22, 2024

Last Update Submit

October 22, 2024

Conditions

Epistaxis

Keywords

Risk FactorsRecurrent Epistaxis

Outcome Measures

Primary Outcomes (1)

  • Survival without bleeding

    Measuring the delay between the first epistaxis and a recurrence.

    1 year

Study Arms (1)

Patient with nose bleeding

Evaluation of recurrence epistaxis during the year after a first episode

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All the patientswho are admitted at the emergency department between 01/2022 and 07/2023

You may qualify if:

  • Patient who is admitted at the emergency department between 01/2022 and 07/2023 for nose bleeding.
  • Age over 18 yo

You may not qualify if:

  • Opposition to be included
  • Patient who has not his willness to provide opposition to participate.opposition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Grenoble Alpes

La Tronche, ISERE, 38700, France

Location

Related Publications (8)

  • Addison A, Paul C, Kuo R, Lamyman A, Martinez-Devesa P, Hettige R. Recurrent epistaxis: predicting risk of 30-day readmission, derivation and validation of RHINO-ooze score. Rhinology. 2017 Jun 1;55(2):99-105. doi: 10.4193/Rhin16.259.

    PMID: 28434017BACKGROUND

  • Abrich V, Brozek A, Boyle TR, Chyou PH, Yale SH. Risk factors for recurrent spontaneous epistaxis. Mayo Clin Proc. 2014 Dec;89(12):1636-43. doi: 10.1016/j.mayocp.2014.09.009. Epub 2014 Nov 6.

    PMID: 25458126BACKGROUND

  • Chaaban MR, Zhang D, Resto V, Goodwin JS. Factors influencing recurrent emergency department visits for epistaxis in the elderly. Auris Nasus Larynx. 2018 Aug;45(4):760-764. doi: 10.1016/j.anl.2017.11.010. Epub 2017 Dec 6.

    PMID: 29208334BACKGROUND

  • Melia L, McGarry GW. Epistaxis: update on management. Curr Opin Otolaryngol Head Neck Surg. 2011 Feb;19(1):30-5. doi: 10.1097/MOO.0b013e328341e1e9.

    PMID: 21150620BACKGROUND

  • Pino Rivero V, Trinidad Ruiz G, Gonzalez Palomino A, Pardo Romero G, Pantoja Hernandez CG, Marcos Garcia M, Keituqwa Yanez T, Blasco Huelva A. [Considerations about ENT emergencies. Analysis of 30000 patients assisted in 10 years]. Acta Otorrinolaringol Esp. 2005 May;56(5):198-201. doi: 10.1016/s0001-6519(05)78600-3. Spanish.

    PMID: 15960122BACKGROUND

  • Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo CA Jr. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med. 2005 Jul;46(1):77-81. doi: 10.1016/j.annemergmed.2004.12.014.

    PMID: 15988431BACKGROUND

  • Tunkel DE, Anne S, Payne SC, Ishman SL, Rosenfeld RM, Abramson PJ, Alikhaani JD, Benoit MM, Bercovitz RS, Brown MD, Chernobilsky B, Feldstein DA, Hackell JM, Holbrook EH, Holdsworth SM, Lin KW, Lind MM, Poetker DM, Riley CA, Schneider JS, Seidman MD, Vadlamudi V, Valdez TA, Nnacheta LC, Monjur TM. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngol Head Neck Surg. 2020 Jan;162(1_suppl):S1-S38. doi: 10.1177/0194599819890327.

    PMID: 31910111BACKGROUND

  • Cohen O, Shoffel-Havakuk H, Warman M, Tzelnick S, Haimovich Y, Kohlberg GD, Halperin D, Lahav Y. Early and Late Recurrent Epistaxis Admissions: Patterns of Incidence and Risk Factors. Otolaryngol Head Neck Surg. 2017 Sep;157(3):424-431. doi: 10.1177/0194599817705619. Epub 2017 May 2.

    PMID: 28463569BACKGROUND

MeSH Terms

Conditions

Epistaxis

Condition Hierarchy (Ancestors)

Nose DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms, RespiratorySigns and Symptoms

Central Study Contacts

Ashley BAGUANT, Doctor

CONTACT

+33476764522abaguant@chu-grenoble.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 22, 2024

First Posted

October 24, 2024

Study Start

November 2, 2024

Primary Completion

March 1, 2025

Study Completion

April 1, 2025

Last Updated

October 24, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)